11:36 AM EDT, 09/04/2025 (MT Newswires) -- Immunovant's ( IMVT ) new batoclimab data show the treatment's potential to offer an alternative to current Graves' disease therapies that often fail to deliver durable results, Oppenheimer said in a note Thursday.

Analysts, including Leland Gershell, said that these results highlight the potential of neonatal Fc receptor, or FcRn, inhibition as a treatment strategy for the 25% to 30% of Graves' patients who relapse or cannot tolerate current therapies. The data also support broader adoption of the approach, as current treatment options often fail to deliver lasting results.

The company's next-generation therapy, IMVT-1402, is currently in phase 3 registration trials and is being given at a consistent higher dose, the analysts said, adding that this longer, higher-dose approach is expected to produce even deeper reductions in immunoglobulin G, or IgG, and improve the chance of lasting remission, with minimal placebo effect.

"We believe IMVT-1402 is setting up to be a best-in-class antiFcRn, with potential to displace first-mover Vyvgart through deep IgG reduction, dosing flexibility tailored for chronic disease, and convenient administration," the analysts said.

They added that Immunovant's ( IMVT ) market value is currently much smaller than competitor Argenx (ARGX), but the company could close that gap as 1402 moves closer to approval.

Oppenheimer has an outperform rating and $54 price target on Immunovant ( IMVT ).

Price: 16.34, Change: -0.36, Percent Change: -2.16